期刊文献+

C-kit和PDGFR-β在硬纤维瘤中的表达及意义

Expression and clinical significance of C-Kit and PDGFR-β in desmoid tumor
下载PDF
导出
摘要 目的研究C-kit和PDGFR-β在硬纤维瘤中的表达及意义。方法采用免疫组化SP法检测C-kit和PDGFR-β在65例硬纤维瘤及其周围正常肌肉组织中的表达。结果 C-kit在硬纤维瘤和周围正常肌肉组织中阳性表达率分别为16.9%和13.8%,P=0.982;PDGFR-β在硬纤维瘤和周围正常肌肉组织中阳性表达率分别为73.8%和15.4%,P=0.024。结论硬纤维瘤肿瘤组织中PDGFR-β高表达,可作为潜在的靶点接受甲磺酸伊玛替尼试验治疗。 Objective To investigate the expression and possible significance of C-Kit and PDGFR-β in desmoid tumor. Methods The expression of C-kit and PDGFR-β in 65 cases of desmoid tumor and the surrounding normal muscle tissue were analyzed with immunohistochemistry SP method. Results The positive expression rate of C-kit in desmoid tumor was 16.9% , not statistically different from the surrounding normal muscle tissue (P = 0. 982). While the positive expression rate of PDGFR-β was 73.8%, statistically higher than the surrounding normal muscle of 15;. 4% (P = 0. 024). Condusions PDGFR-β is highly expressed in desmoid tumor trial evaluation. It could be one potential treatment target for further clinical
机构地区 北京积水潭医院
出处 《山东医药》 CAS 北大核心 2011年第40期17-18,I0001,共3页 Shandong Medical Journal
基金 首都医学发展科研基金资助项目(2005-1009)
关键词 硬纤维瘤 C—kit PDGFR—β desmoid tumor C-kit PDGFR-β
  • 相关文献

参考文献10

  • 1Mace J,Sybil Biermann J,Sondak V,et al.Response of extrasbdominal desmoid tumors to therapy with imatinib mesylate[J].Cancer,2002,95 (11):2373-2379.
  • 2Heinrich MC,McArthur GA,Demetri GD,et al.Clinical and molecular studios of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)[J].J Clin Oncol,2006,24(7):1195-1203.
  • 3Goncalves A,Monges G,Yang Y,et al.Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic a nalysis[J].J Nail Cancer Inst,2006,98(8):562-563.
  • 4Wcislo G,Szarlej-Wcislo K,Szczylik C.Control of aggressive fibro matosis by treatment with imatinib mesylate.A case report and re view of the literature[J].J Cancer Res Clin Oncol,2007,133 (8):533-538.
  • 5Folli F,Galimberti G,Pastore M,et al.Paraneoplastic insulin resistance syndrome in advanced aggressive fibromatosis (desmoid tumor) treated by imatinib mesylate[J].Diabetes Care,2006,29 (9):2178-2180.
  • 6Chung KY,Shia J,Kemeny NE,et al.Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry[J].J Clin Oncol,2005,23(9):1803-1810.
  • 7Buchdunger E,Cioffi CL,Law N,et al.Abl protein-tyrosine kinase inhibitor STL571 inhibits in vitro signal transduction mediated by ckit and platelet-derived growth factor receptors[J].J Pharmacol Exp Ther,2000,295 (1):139-145.
  • 8Yantiss RK,Spiro I J,Compton CC,et al.Gastrointestinal stromal tumor versus intra-abdominal fibromatosis of the bowel wall:a clinically important differential diagnosis[J].Am J Surg Pathol,2000,24(7):947-957.
  • 9Lucas DR,al-Abbadi M,Tabaczka P,et al.c-Kit expression in dosmoid flbromatosis.Comparative immunohistochemical evaluation of two commercial antibodies[J].Am J Clin Pathol,2003,119 (3):339-345.
  • 10Leithner A,Gapp M,Radl R,et al.Immunohistochemical analysis of desmoid tumours[J].J Clin Pathol,2005,58 (11):1152-1156.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部